CL2022003744A1 - Métodos para tratar la alergia usando anticuerpos anti-bet v 1 - Google Patents

Métodos para tratar la alergia usando anticuerpos anti-bet v 1

Info

Publication number
CL2022003744A1
CL2022003744A1 CL2022003744A CL2022003744A CL2022003744A1 CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1 CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1
Authority
CL
Chile
Prior art keywords
bet
antibodies
methods
treat allergy
antigen
Prior art date
Application number
CL2022003744A
Other languages
English (en)
Inventor
Atanasio Amanda
Herman Gary
P O'brien Meagan
M Orengo Jamie
Perlee Lorah
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022003744A1 publication Critical patent/CL2022003744A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona métodos para tratar, prevenir, o mejorar uno o más síntomas de alergia al abedul o enfermedad alérgica en un sujeto mediante la administración al sujeto de un anticuerpo o fragmento de unión al antígeno de este que se une a Bet v 1, o un cóctel de anticuerpos o fragmentos de unión al antígeno de estos que se unen a Bet v 1.
CL2022003744A 2020-07-01 2022-12-23 Métodos para tratar la alergia usando anticuerpos anti-bet v 1 CL2022003744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US202063129253P 2020-12-22 2020-12-22

Publications (1)

Publication Number Publication Date
CL2022003744A1 true CL2022003744A1 (es) 2023-06-02

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003744A CL2022003744A1 (es) 2020-07-01 2022-12-23 Métodos para tratar la alergia usando anticuerpos anti-bet v 1

Country Status (12)

Country Link
US (2) US11897945B2 (es)
EP (1) EP4175986A1 (es)
JP (1) JP2023531968A (es)
KR (1) KR20230030573A (es)
CN (1) CN115698059A (es)
AU (1) AU2021300129A1 (es)
BR (1) BR112022026279A2 (es)
CA (1) CA3177918A1 (es)
CL (1) CL2022003744A1 (es)
IL (1) IL299207A (es)
MX (1) MX2022015677A (es)
WO (1) WO2022006305A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
JPH08501799A (ja) 1992-12-21 1996-02-27 タノックス バイオシステムズ インコーポレイテッド アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
CA3063588A1 (en) * 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途

Also Published As

Publication number Publication date
CA3177918A1 (en) 2022-01-06
US20220002394A1 (en) 2022-01-06
CN115698059A (zh) 2023-02-03
KR20230030573A (ko) 2023-03-06
US11897945B2 (en) 2024-02-13
AU2021300129A1 (en) 2022-12-08
EP4175986A1 (en) 2023-05-10
JP2023531968A (ja) 2023-07-26
BR112022026279A2 (pt) 2023-02-14
MX2022015677A (es) 2023-02-22
IL299207A (en) 2023-02-01
WO2022006305A1 (en) 2022-01-06
US20240209074A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
ECSP17005649A (es) Anticuerpos anti-tau humanizados
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CO2017001317A2 (es) Composición farmacéutica con anticuerpos anti cd40 y kit
EA201301295A1 (ru) Композиции антител против cgrp и их применение
BR112022000719A2 (pt) Anticorpo anti-tau ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo, hibridoma, composição farmacêutica, composição para diagnosticar uma doença neurológica degenerativa, kit, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para prevenir ou tratar uma doença neurológica degenerativa
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112015021979A2 (pt) Anticorpos humanos para grem1
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
PE20170768A1 (es) Anticuerpos de union a protofibrillas ab mejorados
EA202092420A1 (ru) Антитело против pd-l1 и его применение
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
CO2021000386A2 (es) Anticuerpos humanizados contra psma
AR086984A1 (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer
CL2021003335A1 (es) Anticuerpo biespecífico para a-syn/igf1r y uso de este.
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
ZA202302084B (en) Antibody that binds to vegf-a and ang2 and methods of use
CO2022014726A2 (es) Anticuerpos anti-sea de muc1
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
CL2022003744A1 (es) Métodos para tratar la alergia usando anticuerpos anti-bet v 1